Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +16.10%
#2 Fake World Assets Fake World Assets +11.89%
#3 OriginTrail OriginTrail +8.84%
#4 B3 (Base) B3 (Base) +7.77%
#5 Pons Pons +5.38%
#6 Storj Storj +5.13%
#7 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +4.30%
#8 Audiera Audiera +3.81%
#9 Strategy PP Variable xStock Strategy PP Variable xStock +3.03%
#10 Geodnet Geodnet +2.92%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Innstillinger
Språk
NORSK
Valuta
USD
Tema
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.

NGM
Rangering i aksjer #20909
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering... NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.
Aksjekurs
$1.54
Sist synkronisert: 2024-04-08
Markedsverdi
$119.21M
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel NGM Biopharmaceuticals, Inc. (NGM)

Kategori

Healthcare
Antall utestående aksjer for NGM Biopharmaceuticals, Inc. (NGM)
Antall utestående aksjer per August 2026: 0
Ifølge NGM Biopharmaceuticals, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 0. Ved slutten av August 2026 hadde selskapet 0 utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for NGM Biopharmaceuticals, Inc. (NGM) fra 2026 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
Ikke nok data for de angitte datoene.
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH